Anixa Biosciences, Inc. (NASDAQ: ANIX) is a Healthcare company (Biotechnology) with a market capitalization of $93M. The Maz Rating grades it against the other companies in its sector.
Anixa Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.67, Anixa Biosciences, Inc. trades at 6.2x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -70.4%, return on invested capital of -82.1% and a free cash flow yield of -7.9%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 8.54. Over the past 52 weeks the share price ranged from $2.32 to $5.46, with a beta of 0.60.
Anixa Biosciences, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.